The AhR‐SRC axis as a therapeutic vulnerability in BRAFi‐resistant melanoma
Open Access
- 28 October 2022
- journal article
- research article
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 14 (12) , e15677
Abstract
The nongenetic mechanisms required to control tumor phenotypic plasticity and shape drug‐resistance remain unclear. We show here that the Aryl hydrocarbon Receptor (AhR) transcription factor directly regulates the gene expression program associated with the acquisition of resistance to BRAF inhibitor (BRAFi) in melanoma. In addition, we show in melanoma cells that canonical activation of AhR mediates the activation of the SRC pathway and promotes the acquisition of an invasive and aggressive resistant phenotype to front‐line BRAFi treatment in melanoma. This nongenetic reprogramming identifies a clinically compatible approach to reverse BRAFi resistance in melanoma. Using a preclinical BRAFi‐resistant PDX melanoma model, we demonstrate that SRC inhibition with dasatinib significantly re‐sensitizes melanoma cells to BRAFi. Together we identify the AhR/SRC axis as a new therapeutic vulnerability to trigger resistance and warrant the introduction of SRC inhibitors during the course of the treatment in combination with front‐line therapeutics to delay BRAFi resistance.Keywords
Funding Information
- Association Recherche contre le Cancer (PGA1*20160203868)
- College of Natural Resources and Sciences, Humboldt State University
- FHU CAMIn‐CHU RENNES
- Institut National de la Santé et de la Recherche Médicale
- CNIB (ENV201308)
- CNIB (ENV201603)
- Ligue Contre le Cancer
- Stichting Tegen Kanker (2016‐054)
- Université de Rennes 1
This publication has 85 references indexed in Scilit:
- Cellular Functions Regulated by Phosphorylation of EGFR on Tyr845International Journal of Molecular Sciences, 2013
- Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cellsNucleic Acids Research, 2012
- CellMiner: A Web-Based Suite of Genomic and Pharmacologic Tools to Explore Transcript and Drug Patterns in the NCI-60 Cell Line SetCancer Research, 2012
- Src-mediated aryl hydrocarbon and epidermal growth factor receptor cross talk stimulates colon cancer cell proliferationAmerican Journal of Physiology-Gastrointestinal and Liver Physiology, 2012
- The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivityNature, 2012
- A phase 2 trial of dasatinib in advanced melanomaCancer, 2010
- The Aryl Hydrocarbon Receptor-interacting Protein (AIP) Is Required for Dioxin-induced Hepatotoxicity but Not for the Induction of the Cyp1a1 and Cyp1a2 GenesJournal of Biological Chemistry, 2010
- Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanomaNature, 2010
- Mitf regulation of Dia1 controls melanoma proliferation and invasivenessGenes & Development, 2006
- Mutations of the BRAF gene in human cancerNature, 2002